After 14 years, the Final Destination series returned to theaters with this weekend’s Bloodlines, and audiences flocked to see some young adults perish.
Per Variety, the horror flick has earned $102 million worldwide, a new best for the series. That take is an even split (heh) of $51 million domestically and internationally. For reference, The Final Destination and Final Destination 5 opened to $28.3 and $18.4 million in their respective weekends without inflation. It’s good Bloodlines got a theatrrical release instead of opening on HBO Max, because its reception has been pretty high—critics were mixed or negative on earlier movies, but this one is the best-reviewed in the series. Audience reception has been just as strong, helped by some nostalgically terrifying marketing and the film offering a sendoff for series mainstay Tony Todd, who passed away in 2024.
Final Destination Bloodlines isn’t Warner Bros.’ only horror hit. Sinners continues to make money. Domestically, it’s made another $15.4 million in its fifth weekend, bringing its total to $240.8 million and $316 million worldwide. Part of that can be attributed to its recent return to IMAX after it took time off to accomodate for Thunderbolts*’ and Bloodlines taking its theaters. It’s still playing in the format Wednesday, May 21, so go see it while you can. Speaking of Thunderbolts*, the Marvel team-up flick upped its take to $155.4 million domestic and $325 million global. Right now, it’s on the low end of Marvel’s Phase Five films, ahead of The Marvels ($206.1 million) and behind Captain America: Brave New World ($415.1 million) and Ant-Man & the Wasp: Quantumania ($476.1 million).
Next weekend has Mission: Impossible—The Final Reckoning and the Lilo & Stitch remake. There’s a lot of momentum behind both going into Memorial Day, so expect them to post big numbers.
Want more io9 news? Check out when to expect the latest Marvel, Star Wars, and Star Trek releases, what’s next for the DC Universe on film and TV, and everything you need to know about the future of Doctor Who.
Read the full article here
